164 related articles for article (PubMed ID: 16171861)
1. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
Seshadri T; Hourigan MJ; Wolf M; Mollee PN; Seymour JF
Leuk Res; 2006 Apr; 30(4):483-5. PubMed ID: 16171861
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
4. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
5. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
[TBL] [Abstract][Full Text] [Related]
6. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
[TBL] [Abstract][Full Text] [Related]
7. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648
[TBL] [Abstract][Full Text] [Related]
8. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia.
Xu W; Li JY; Qian SX; Wu HX; Lu H; Chen LJ; Zhang SJ; Lu RL; Sheng RL
Leuk Res; 2008 Jun; 32(6):930-5. PubMed ID: 18061665
[TBL] [Abstract][Full Text] [Related]
9. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma.
Dann EJ; Epelbaum R; Avivi I; Ben Shahar M; Haim N; Rowe JM; Blumenfeld Z
Hum Reprod; 2005 Aug; 20(8):2247-9. PubMed ID: 15817583
[TBL] [Abstract][Full Text] [Related]
10. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
[TBL] [Abstract][Full Text] [Related]
11. Progressive paresthesia and weakness after intrathecal chemotherapy.
Marshall R; Gupta ND; Palacios E; Neitzschman HR
J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
[TBL] [Abstract][Full Text] [Related]
12. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
13. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
O'Brien S; Thomas DA; Ravandi F; Faderl S; Pierce S; Kantarjian H
Cancer; 2008 Oct; 113(8):2097-101. PubMed ID: 18720356
[TBL] [Abstract][Full Text] [Related]
14. [An adult case of precursor B cell lymphoblastic lymphoma extending from right neck to upper cervical spinal region].
Nishihara M; Kudo H; Mizuno I; Taomoto K; Kohmura E
No Shinkei Geka; 2005 Nov; 33(11):1107-11. PubMed ID: 16277225
[TBL] [Abstract][Full Text] [Related]
15. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
Alduaij A; Butera JN; Treaba D; Castillo J
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
[TBL] [Abstract][Full Text] [Related]
16. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
[TBL] [Abstract][Full Text] [Related]
19. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
Keane C; Gibbs S; Seymour JF; Mills AK; Grimmett K; Van Kuilenberg R; Saal R; Gill D; Prince HM; Marlton P; Mollee P
Hematol Oncol; 2006 Sep; 24(3):159-63. PubMed ID: 16775841
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]